Pharmaceutical composition containing fbpase-inhibiting agent
A composition and inhibitor technology, applied in the field of pharmaceutical compositions containing FBPase inhibitors, can solve the problems of unknown significant improvement of pancreatic β-cell function and other issues
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment
[0061] The FBPase inhibitory activity of the test compound can be determined according to the method of International Publication No. WO00 / 14095. 2-Amino-5-isobutyl-4-{2-[5-(N,N'-bis((S)-1-ethoxycarbonyl)ethyl)phosphonamido]furyl}thiazole (compound A) It can be prepared according to the method of International Publication No. WO01 / 47935.
[0062] Insulin sensitizer 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione hydrochloride ( Compound B) can be produced according to the methods described in JP-A-9-295970, EP-0745600, USP-5886014 and WO00 / 71540.
[0063] Insulin sensitizer 5-(4-((6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy)benzyl)-2,4-thiazole Alkanediones (troglitazone; compound T) can be produced according to the methods of US Patent No. 4,572,912 and Japanese Patent Publication No. Hei 2-31079.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com